EP1939279A1 - Hautmodell - Google Patents

Hautmodell Download PDF

Info

Publication number
EP1939279A1
EP1939279A1 EP07122035A EP07122035A EP1939279A1 EP 1939279 A1 EP1939279 A1 EP 1939279A1 EP 07122035 A EP07122035 A EP 07122035A EP 07122035 A EP07122035 A EP 07122035A EP 1939279 A1 EP1939279 A1 EP 1939279A1
Authority
EP
European Patent Office
Prior art keywords
skin
sample
acid
pig
skin sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07122035A
Other languages
English (en)
French (fr)
Other versions
EP1939279B1 (de
Inventor
Gabriele Vielhaber
Paolo Pertile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symrise AG
Cutech SRL
Original Assignee
Symrise AG
Cutech SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06125283A external-priority patent/EP1927656A1/de
Application filed by Symrise AG, Cutech SRL filed Critical Symrise AG
Priority to EP20070122035 priority Critical patent/EP1939279B1/de
Publication of EP1939279A1 publication Critical patent/EP1939279A1/de
Application granted granted Critical
Publication of EP1939279B1 publication Critical patent/EP1939279B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts

Definitions

  • a skin sample is viable and completely functional as long as both of the following conditions are fulfilled:
  • the skin samples are of a domestic pig (Sus scorofa, sometimes also termed Sus domesticus), most preferably a Pietrain or a Landrace hybrid pig.
  • Pietrain pig skin is particularly preferred since this race has a partly pigmented skin and thus allows the assessment of skin pigmentation effectors, i.e. tanning substances and skin whitening substances.
  • a skin sample with an epidermis surface area of 9-25 mm 2 to comprise at least three hair follicles, more preferably at least four hair follicles, and still more preferred at least five hair follicles.
  • a suitable transport medium is (Dulbecco Modified Eagle Medium (DMEM) with added penicillin (100U/ml) and streptomycin (100 ⁇ g/ml).
  • DMEM Dulbecco Modified Eagle Medium
  • penicillin 100U/ml
  • streptomycin 100 ⁇ g/ml
  • the excised skin patch is treated for not more than 4 hours, preferably not more than 3 hours with transport medium.
  • Fast processing of the skin patches to obtain skin samples aids in ensuring minimal or no skin degeneration.
  • the edges of skin patches are cut and discarded.
  • the remaining skin sample is placed on a sterile support, preferably cork, and cut to the desired sizes as given above, preferably to a size of 4x4x3 mm (length x width x thickness).
  • the skin samples are used for the assessment of one or more of the following effects, preferably caused by the application of a putatively effect-causing substance or other treatment:
  • the substances the effects of which are to be assessed by the skin model are applied topically by application to the epidermis, or systemically by addition to a cultivation medium.
  • the substances can be applied in any form, including application as a pure substance, or a mixture with one or more other substances (that may or may not have effects on a skin model).
  • the substance or substances can be applied as a solid, a gel, a cream or other multi-phase composition, a liquid, a foam or a gas.
  • auxiliary substances and additives can be present in formulations in amounts advantageously of 5 - 99 wt.%, preferably of 10 - 80 wt.%, based on the total weight of the mixture.
  • the formulations can also contain water in an amount of up to 99.99 wt.%, preferably of 5 - 80 wt.%, based on the total weight of the formulation.
  • citric acid, malic acid, L-, D- or DL-lactic acid skin colourants
  • active ingredients for promoting hair growth e.g. minoxidil, diphencyprone, hormones, finasteride, phytosterols such as beta-sitosterol, biotin, or extracts of Cimicifuga racemosa, Eugenia caryophyllata or Hibiscus rosasinensis, barley, hops, or rice or wheat hydrolysates
  • skin care products e.g. cholesterol, ceramides, pseudoceramides
  • softening moisturizing and/or moisture-retaining substances
  • cosmetic or dermatological auxiliary substances and additives and perfume to be used can readily be determined by those skilled in the art on a simple trial-and-error basis, as a function of the particular type of product.
  • the total amount of filter substances is from 0.01 wt.% to 40 wt.%, preferably from 0.1% to 10 wt.% and particularly preferably from 1.0 to 5.0 wt.%, based on the total weight of the mixture, in order to provide cosmetic mixtures (preparations).
  • UV absorbers are particularly suitable for combination:
  • Advantageous inorganic light-protecting pigments are finely disperse metal oxides and metal salts, for example titanium dioxides, zinc oxide (ZnO), iron oxides (e.g. Fe 2 O 3 ), aluminium oxide (Al 2 O 3 ), cerium oxides (e.g. Ce 2 O 3 ), manganese oxides (e.g. MnO), zirconium oxide (ZrO 2 ), silicon oxide (SiO 2 ), mixed oxides of the corresponding metals, and mixtures of such oxides, barium sulfate and zinc stearate.
  • Particularly preferred pigments are those based on TiO 2 or zinc oxide.
  • suitable hydrophobic coating agents being primarily silicones and especially trialkoxyoctylsilanes or simethicones.
  • micropigments or nanopigments are preferably used in sunscreen products, zinc micropigments or nanopigments being particularly preferred.
  • the total amount of inorganic pigments, especially hydrophobic inorganic micropigments, in the finished cosmetic or dermatological formulations advantageously ranges from 0.1 to 30 wt.%, preferably from 0.1 to 10.0 and particularly preferably from 0.5 to 6.0 wt.%, based on the total weight of the formulations.
  • Anti-irritants apart from (alpha-)bisabolol can also be used in or as formulations to be tested with the aid of the pig skin model according to the invention.
  • Anti-irritants can be any anti-inflammatory or redness-alleviating and antipruritic substances that are suitable or customary for cosmetic and/or dermatological applications.
  • Preferred anti-inflammatory or redness-alleviating and antipruritic substances (anti-irritants) are steroidal anti-inflammatory substances of the corticosteroid type, e.g. hydrocortisone, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone, it being possible to extend the list by adding other steroidal anti-inflammatories.
  • Non-steroidal anti-inflammatories can also be used.
  • oxicams such as piroxicam or tenoxicam
  • salicylates such as aspirin, Disalcid, Solprin or fendosal
  • acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac
  • fenamates such as mefenamic, meclofenamic, flufenamic or niflumic
  • propionic acid derivatives such as ibuprofen, naproxen or benoxaprofen
  • pyrazoles such as phenylbutazone, oxyphenylbutazone, febrazone or azapropazone.
  • panthenol e.g. avenanthramides
  • oats e.g. avenanthramides
  • Echinacea e.g. Echinacea
  • the formulations can also be or contain antioxidants, it being possible to use any antioxidants suitable or customary for cosmetic and/or dermatological applications.
  • the antioxidants are advantageously selected from the group comprising amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, peptides such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotenoids, carotenes (e.g.
  • ⁇ -carotene, ⁇ -carotene, lycopene) and derivatives thereof chlorogenic acid and derivatives thereof, lipoic acid and derivatives thereof (e.g. dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (e.g.
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl, lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts), sulfoximine compounds (e.g.
  • buthionine sulfoximine homocysteine sulfoximine, buthionine sulfone, penta-, hexa-, heptathionine sulfoximine
  • metal chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin, ⁇ -hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof, unsaturated fatty acids and derivatives thereof (e.g.
  • vitamin E acetate
  • vitamin A and derivatives thereof vitamin A palmitate
  • the amount of antioxidants (one or more compounds) in the formulations is preferably 0.01 to 20 wt.%, particularly preferably 0.05 - 10 wt.% and very particularly preferably 0.2 - 5 wt.%, based on the total weight of the preparation.
  • vitamin E and/or its derivatives represent the antioxidant(s)
  • their respective concentrations are advantageously chosen from the range between 0.001 and 10 wt.%, based on the total weight of the formulation.
  • citric acid lactic acid, malic acid
  • mono-, di- and oligosaccharides such as glucose, galactose, fructose, mannose, fruit sugar and lactose
  • polysugars such as ⁇ -glucans, especially 1,3-1,4- ⁇ -glucan from oats, alpha-hydroxy fatty acids, triterpene acids such as betulinic acid or ursolic acid, and algae extracts.
  • the formulations can also be or used together with osmolytes.
  • osmolytes substances from the group comprising sugar alcohols (myoinositol, mannitol, sorbitol), quaternary amines such as taurine, choline, betaine, betaine glycine and ectoine, diglyceryl phosphate, phosphorylcholine, glycerophosphorylcholine, amino acids such as glutamine, glycine, alanine, glutamate, aspartate or proline, phosphatidylcholine, phosphatidylinositol, inorganic phosphates, and polymers of said compounds such as proteins, peptides, polyamino acids and polyols. All osmolytes have a skin-moisturizing effect at the same time.
  • formulations can also be or contain active substances which stimulate skin and hair tinting or bronzing in a chemical or natural way, thereby achieving a more rapid action based on synergistic effects.
  • said substances are substrates or substrate analogues of tyrosinase, such as L-tyrosine, L-DOPA or L-dihydroxyphenylalanine, stimulators of tyrosinase activity or expression, such as theophylline, caffeine, proopiomelanocortin peptides such as ACTH, alpha-MSH, their peptide analogues and other substances that bind to the melanocortin receptor, peptides such as Val-Gly-Val-Ala-Pro-Gly, Lys-lle-Gly-Arg-Lys or Leu-lle-Gly-Lys, purines, pyrimidines, folic acid, copper salts such as copper gluconate, chloride or pyrrolidon
  • bearberry extract such as glabridin or licochalcone A, Artocarpus extract, extract of Rumex and Ramulus species, extracts of pine species (Pinus) and extracts of Vitis species or stilbene derivatives obtained therefrom by enrichment, and extracts of Saxifraga, mulberry, Scutelleria and/or grapes.
  • the cationic surfactants used can also preferably be selected from the group comprising quaternary ammonium compounds, especially benzyltrialkylammonium chlorides or bromides, for example benzyldimethylstearylammonium chloride, alkyltrialkylammonium salts, for example cetyltrimethylammonium chloride or bromide, alkyldimethylhydroxyethylammonium chlorides or bromides, dialkyldimethylammonium chlorides or bromides, alkylamidoethyltrimethylammonium ether sulfates, alkylpyrimidinium salts, for example laurylpyrimidinium or cetylpyridinium chloride, imidazoline derivatives, and compounds of cationic character, such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Cetyltrimethylammonium salts can be used to particular advantage.
  • Nurturing substances which are outstandingly suitable as or for combination with the formulations used according to the invention also include the following:
  • ethanol isopropanol, 1,2-propanediol and glycerol, and especially one or more thickeners which can advantageously be selected from the group comprising silicon dioxide, aluminium silicates, polysaccharides or derivatives thereof, e.g. hyaluronic acid, xanthan gum and hydroxypropyl methyl cellulose, and particularly advantageously from the group comprising polyacrylates, preferably a polyacrylate from the group comprising so-called carbopols, e.g. carbopols of types 980, 981, 1382, 2984 and 5984, each individually or in combination.
  • carbopols e.g. carbopols of types 980, 981, 1382, 2984 and 5984, each individually or in combination.
  • the polyethoxylated, polypropoxylated or polyethoxylated and polypropoxylated O/W emulsifiers used are particularly advantageously selected from the group of substances with HLB values of 11 - 18, and very particularly advantageously from those with HLB values of 14.5 - 15.5, if they contain saturated radicals R and R'. If the O/W emulsifiers contain unsaturated radicals R and/or R', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers can also be lower or higher.
  • Sodium laureth-11 carboxylate can advantageously be used as an ethoxylated alkyl ether carboxylic acid or a salt thereof.
  • Sodium laureth-1-4 sulfate can advantageously be used as an alkyl ether sulfate.
  • Polyethylene glycol (30) cholesteryl ether can advantageously be used as an ethoxylated cholesterol derivative.
  • Polyethylene glycol (25) soya sterol has also proved valuable.
  • lidocaine, prilocaine or mixtures of such substances which switch off the sympathetic supply to the sweat glands by blocking the peripheral nerve paths
  • zeolites of the X, A or Y type which, in addition to reducing sweat secretion, also act as adsorbents of bad odours
  • botulinum toxin toxin of the bacterium Chlostridium botulinum
  • the amount of deodorizing and/or antiperspirant substances in the mixtures is preferably 0.01 to 20 wt.% and particularly preferably 0.05 - 10 wt.%, based on the total weight of the preparations.
  • the area of the skin to be excised was washed with distilled water, and then dried with sterile gauzes. Afterwards, the hair shafts were cut by using an electric clipper at a length of 1 mm. Subsequently, all the dorsal skin was washed by using a surgical soap that was then removed by plugging with sterile gauzes soaked in distilled water. Afterwards, the skin was further cleaned with chlorhexidine and then dried with sterile gauzes. Lastly, the skin was restored by using a physiological solution.
  • the patch was lifted carefully by the use of tweezers and, by using a scalpel, the skin including epidermis, dermis and fat layer was gently detached from the muscle.
  • the fat layer was further reduced to a maximum thickness of 3 mm to which allows optimal nutrition of the tissue from the culture medium.
  • the skin patches were transferred into William's E medium as the culture medium.
  • Skin viability was controlled by verifying the rate of both skin and hair cell apoptosis and proliferation.
  • the skin is strictly kept on sterile environment. This procedure assures acceptable conditions of skin viability up to 21 days.
  • Example 4 Use of baby pig skin for the screening of potential modulator of hair growth
  • CsA and TGFb2 have shown to stimulate and inhibit, respectively, hair matrix cell proliferation, suggesting to have exerted the expected modulatory action on hair growth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cosmetics (AREA)
EP20070122035 2006-12-01 2007-11-30 Hautmodell Active EP1939279B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20070122035 EP1939279B1 (de) 2006-12-01 2007-11-30 Hautmodell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125283A EP1927656A1 (de) 2006-12-01 2006-12-01 Hautmodell
EP20070122035 EP1939279B1 (de) 2006-12-01 2007-11-30 Hautmodell

Publications (2)

Publication Number Publication Date
EP1939279A1 true EP1939279A1 (de) 2008-07-02
EP1939279B1 EP1939279B1 (de) 2012-07-11

Family

ID=39446251

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20070122035 Active EP1939279B1 (de) 2006-12-01 2007-11-30 Hautmodell

Country Status (1)

Country Link
EP (1) EP1939279B1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096645A1 (en) * 2011-12-20 2013-06-27 The Procter & Gamble Company Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation
CN103345862A (zh) * 2013-07-15 2013-10-09 苏州大学 一种血球计数板教具
US9341618B2 (en) 2007-02-22 2016-05-17 Kao Corporation Method for evaluating or screening hair growth-regulating agent

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740186A1 (de) 1987-06-24 1989-01-05 Beiersdorf Ag Desodorierende und antimikrobielle zusammensetzung zur verwendung in kosmetischen oder topischen zubereitungen
DE3938140A1 (de) 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
DE4009347A1 (de) 1990-03-23 1991-09-26 Beiersdorf Ag Desodorierende kosmetische mittel
DE4204321A1 (de) 1992-02-13 1993-08-19 Beiersdorf Ag Verfahren zur isolierung und reinigung von fettsaeuren und hydroxyfettsaeuren und verwendungen von hydroxyfettsaeuren sowie zubereitungen, die sie enthalten
DE4229737A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Desodorierende kosmetische Mittel mit einem Gehalt an Fettsäuren
DE4229707A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Germicide Wirkstoffkombinationen
DE4237081A1 (de) 1992-11-03 1994-05-05 Beiersdorf Ag Desodorierende kosmetische Zubereitungen mit einem Gehalt an Di- oder Triglycerinestern
DE4309372A1 (de) 1993-03-23 1994-09-29 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von Wollwachssäuren und Partialglyceriden
DE4324219A1 (de) 1993-07-20 1995-01-26 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Wollwachssäuren
WO2002038537A1 (de) 2000-11-10 2002-05-16 Haarmann & Reimer Gmbh Neue indanylidenverbindungen
WO2004092726A1 (de) * 2003-04-15 2004-10-28 Universitätsklinikum Hamburg-Eppendorf Ex-vivo-hautorganmodell aus schweinehaut
DE10317402A1 (de) 2003-04-15 2004-11-11 Universitätsklinikum Hamburg-Eppendorf Ex-vivo-Hautorganmodell, insbesondere für männliche Haut

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740186A1 (de) 1987-06-24 1989-01-05 Beiersdorf Ag Desodorierende und antimikrobielle zusammensetzung zur verwendung in kosmetischen oder topischen zubereitungen
DE3938140A1 (de) 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
DE4009347A1 (de) 1990-03-23 1991-09-26 Beiersdorf Ag Desodorierende kosmetische mittel
DE4204321A1 (de) 1992-02-13 1993-08-19 Beiersdorf Ag Verfahren zur isolierung und reinigung von fettsaeuren und hydroxyfettsaeuren und verwendungen von hydroxyfettsaeuren sowie zubereitungen, die sie enthalten
DE4229737A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Desodorierende kosmetische Mittel mit einem Gehalt an Fettsäuren
DE4229707A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Germicide Wirkstoffkombinationen
DE4237081A1 (de) 1992-11-03 1994-05-05 Beiersdorf Ag Desodorierende kosmetische Zubereitungen mit einem Gehalt an Di- oder Triglycerinestern
DE4309372A1 (de) 1993-03-23 1994-09-29 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von Wollwachssäuren und Partialglyceriden
DE4324219A1 (de) 1993-07-20 1995-01-26 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Wollwachssäuren
WO2002038537A1 (de) 2000-11-10 2002-05-16 Haarmann & Reimer Gmbh Neue indanylidenverbindungen
DE10055940A1 (de) 2000-11-10 2002-05-29 Bayer Ag Neue Indanylidenverbindungen
WO2004092726A1 (de) * 2003-04-15 2004-10-28 Universitätsklinikum Hamburg-Eppendorf Ex-vivo-hautorganmodell aus schweinehaut
DE10317402A1 (de) 2003-04-15 2004-11-11 Universitätsklinikum Hamburg-Eppendorf Ex-vivo-Hautorganmodell, insbesondere für männliche Haut
DE10317400A1 (de) 2003-04-15 2004-11-18 Universitätsklinikum Hamburg-Eppendorf EX-VIVO-Hautorganmodell aus Schweinehaut

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BRAIN ET AL., OOD. CHEM. TOXICOL, vol. 43, 2005, pages 681 - 690
GERDES J ET AL., J IMMUNOL, vol. 133, 1984, pages 1710 - 5
GORE ANURADHA V ET AL: "Comparative biomembrane permeation of tacrine using Yucatan minipigs and Domestic pigs as the animal model", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 87, no. 4, April 1998 (1998-04-01), pages 441 - 447, XP002430715, ISSN: 0022-3549 *
JACOBS J J L ET AL: "METHYL GREEN-YPRONINE STAINING OF PORCINE ORGANOTYPIC SKIN EXPLANT CULTURES: AN ALTERNATIVE MODEL FOR SCREENING FOR SKIN IRRITANTS", ATLA. ALTERNATIVES TO LABORATORY ANIMALS, LONDON, GB, vol. 28, 2000, pages 279 - 292, XP009038188, ISSN: 0261-1929 *
KASTING ET AL., PHARM. RES, vol. 7, 1990, pages 1141 - 1146
MEYER W ET AL: "THE SKIN OF DOMESTIC MAMMALS AS A MODEL FOR THE HUMAN SKIN, WITH SPECIAL REFERENCE TO THE DOMESTIC PIG", CURRENT PROBLEMS IN DERMATOLOGY, KARGER, BASEL, CH, vol. 7, 1978, pages 39 - 52, XP009033716, ISSN: 1421-5721 *
MEYER W ET AL: "UNTERSUCHUNGEN ZUR STRUKTUR DER OHRHAUT BEIM HAUSSCHWEIN, UNTER BESONDERER BERUEKSICHTIGUNG EINER VERWENDUNG IN DER HUMANDERMATOLOGISCHEN FORSCHUNG INVESTIGATION IN THE STRUCTURE OF THE EAR SIN IN THE DOMESTICATED PIG, WITH SPECIAL REFERENCE TO THE USE FOR HUMAN DERMATOLOGICAL RESEARCH", BERLINER UND MUENCHENER TIERAERZTLICHE WOCHENSCHRIFT, PAUL PAREY, BERLIN, DE, vol. 114, no. 3/4, 2001, pages 92 - 111, XP009038241, ISSN: 0005-9366 *
MEYER, W ET AL., CURR. PROBL. DERMATOL, vol. 7, 1978, pages 39 - 52
MISAGO ET AL., BR. J. DERMATOL, vol. 139, 1998, pages 40 - 48
MOISON RALF M W ET AL: "Topically applied vitamin C and cysteine derivatives protect against UVA-induced photodegradation of suprofen in ex vivo pigskin.", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 77, no. 4, April 2003 (2003-04-01), pages 343 - 348, XP009082731, ISSN: 0031-8655 *
RIJNKELS ET AL., PHOTOCHEM., PHOTOBIOL, vol. 73, no. 5, 2001, pages 499 - 504
RIJNKELS JOLANDA M ET AL: "TIME AND DOSE-RELATED ULTRAVIOLET B DAMAGE IN VIABLE PIG SKIN EXPLANTS HELD IN A NEWLY DEVELOPED ORGAN CULTURE SYSTEM", PHOTOCHEMISTRY AND PHOTOBIOLOGY, OXFORD, GB, vol. 73, no. 5, 1 May 2001 (2001-05-01), pages 499 - 504, XP009082730, ISSN: 0031-8655 *
SINTOV ET AL., INT. J. PHARM, vol. 27, 2006, pages 55 - 62
STENN ET AL., PHYSIOL. REF., vol. 81, 2001, pages 479
SUGIHARA ET AL., BR. J. DERMATOL, vol. 144, 2001, pages 244 - 253

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9341618B2 (en) 2007-02-22 2016-05-17 Kao Corporation Method for evaluating or screening hair growth-regulating agent
WO2013096645A1 (en) * 2011-12-20 2013-06-27 The Procter & Gamble Company Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation
WO2013096639A1 (en) * 2011-12-20 2013-06-27 The Procter & Gamble Company Human skin sample methods and models for assessing tone-specific benefits of agents
US10732171B2 (en) 2011-12-20 2020-08-04 The Procter & Gamble Company Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation
CN103345862A (zh) * 2013-07-15 2013-10-09 苏州大学 一种血球计数板教具

Also Published As

Publication number Publication date
EP1939279B1 (de) 2012-07-11

Similar Documents

Publication Publication Date Title
EP2019316B1 (de) Menschliches ex-vivo-Hautmodell
EP1816998B1 (de) Formulierungen mit ceramiden und/oder pseudoceramiden und (alpha-)bisabolol zur behandlung von hautschäden
US20080268077A1 (en) Process for Strengthening the Barrier Function of Undamaged Skin
Ponec Skin constructs for replacement of skin tissues for in vitro testing
US20080138850A1 (en) Skin Model
US20080305054A1 (en) Use of Glycosylated Flavanones for the Browning of Skin or Hair
EP1959915B1 (de) Gemische mit anthranilsäureamiden und anti-schuppen-mittel als kosmetische und pharmazeutische zusammensetzungen zur linderung von juckreiz
US20100216892A1 (en) Use of synergistically active 1,2-alkanediol mixtures as skin moisture-regulating compositions
Bessou-Touya et al. Chimeric human epidermal reconstructs to study the role of melanocytes and keratinocytes in pigmentation and photoprotection
EP1937366A1 (de) Synergistische mischungen aus bisabolol und ingwerextrakt
WO2006134013A1 (en) Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching
EP1939279B1 (de) Hautmodell
BR112021015826A2 (pt) Composição cosmética
JP6194003B2 (ja) 有益剤及びこれを含む組成物の特定又は評価方法
Zoio et al. Open-source human skin model with an in vivo-like barrier for drug testing
JP2017536803A (ja) 皮膚の老化の防止および／または緩和、および／または皮膚の保湿、および／または皮膚色素沈着の抑制のためのセストリン（ｓｅｓｔｒｉｎ）アクチベーター
JP6189962B2 (ja) 相乗作用する美容成分の組み合わせを特定する方法
EP1893161A1 (de) Gemische mit anthranilinsäureamiden und kühlenden mitteln als kosmetische und pharmazeutische zusammensetzungen zur linderung von juckreiz
JP2017221189A (ja) 敏感肌評価用装置及びこれを用いた評価方法
Bause et al. More than skin deep: the human skin tissue equivalent as an advanced drug discovery tool
WO2021176074A1 (en) Composition comprising an avenanthramide with improved skin penetration
Zoio Open-source human sin model with an in vivo-like barrier for drug irritation and permeation testing
Schmid et al. Research Article A standardized method based on pigmented epidermal models evaluates sensitivity against UV-irradiation1
KR20110091276A (ko) 피부자극 예측 평가방법 및 평가키트

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20081104

17Q First examination report despatched

Effective date: 20081209

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CUTECH S.R.L.

Owner name: SYMRISE GMBH & CO. KG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CUTECH S.R.L.

Owner name: SYMRISE AG

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602007023900

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0005060000

Ipc: G01N0033500000

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101AFI20110909BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 566384

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007023900

Country of ref document: DE

Effective date: 20120906

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120711

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 566384

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120711

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Effective date: 20120711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121111

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121012

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121112

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121022

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

26N No opposition filed

Effective date: 20130412

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20121130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121011

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007023900

Country of ref document: DE

Effective date: 20130412

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130731

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231120

Year of fee payment: 17